Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Show more
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias PR Newswire SAN DIEGO and TOKYO, Nov. 20, 2024 – Kura to receive a...
– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase...
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th – – Ziftomenib combined with ven/aza in R/R NPM1-m or...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.815 | -10.23977433 | 17.725 | 17.94 | 15.42 | 834014 | 16.04828107 | CS |
| 4 | -1.94 | -10.8683473389 | 17.85 | 19.7283 | 15.42 | 835540 | 17.30666885 | CS |
| 12 | -4.4 | -21.6642048252 | 20.31 | 21.569 | 15.42 | 603492 | 18.29757496 | CS |
| 26 | -6.15 | -27.878513146 | 22.06 | 23.48 | 15.42 | 648708 | 19.59841155 | CS |
| 52 | 6.49 | 68.8959660297 | 9.42 | 24.17 | 9.06 | 912519 | 18.67254163 | CS |
| 156 | -1.2 | -7.01344243133 | 17.11 | 24.17 | 7.41 | 845440 | 15.10280006 | CS |
| 260 | 0.79 | 5.22486772487 | 15.12 | 43 | 6.34 | 752112 | 17.95244748 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
